RxDoctor Payments Data

Carrie Willis, MD

Cardiovascular Disease · St George, UTNPI 1811151020

Payments from drug & device makers

$668in general payments, 2019–2025

Across 22 payments — averaging $30.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$191
  • Abbott$143
  • Alnylam Pharmaceuticals Inc.$115
  • Merck$77
  • Boston Scientific$66
  • E.r. Squibb & Sons, L.L.C.$45
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$63996%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$668 in reported general payments places this provider in the 35th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$62,319
Medicare patients
395
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis28$654,543
FarxigaDapagliflozin Propanediol56$59,509
EntrestoSacubitril/Valsartan51$57,006
JardianceEmpagliflozin52$56,673
EliquisApixaban34$42,716
Torsemide71$2,468
Eplerenone28$2,265
Metoprolol Succinate117$1,746
Spironolactone127$1,201
Losartan Potassium101$1,151
Liothyronine Sodium16$820
Lisinopril67$747
Atorvastatin Calcium51$712
Isosorbide Mononitrate ErIsosorbide Mononitrate49$656
Carvedilol80$564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$191$697,25962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →